| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
* Pathobiological Sciences and
Laboratory Medicine and Pathology, University of Wisconsin, Madison, WI 53706;
Department of Internal Medicine, Washington University, St. Louis, MO 63110;
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201; and
¶ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In recent times, there has been a surge in studying the role of complement proteins in regulating T cell responses. Recent reports have provided strong evidence that C3 might be important in the elicitation of T cell responses during autoimmune myocarditis, influenza infection, and acute renal graft rejection in mice (16, 17, 18). However, the role of C3 in the activation and expansion of T cells during a systemic infection has not been examined. To address this issue, we determined the role of C3 in the generation of Ag-specific CD8 T cell responses following an acute infection with lymphocytic choriomeningitis virus (LCMV) in wild-type (+/+), C3-deficient (C3-/-), and CR1/CR2-deficient (CR1/CR2-/-) mice. Our studies provide strong evidence that C3 promotes CD8 T cell responses in an epitope-specific manner, which is influenced by the genetic background of mice.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The C3-/- mice on the 129/C57BL6 background (C3-/- 129/B6) were kindly provided by Dr. H. R. Colten (Washington University, St. Louis, MO) (19). The control wild-type 129/B6 mice (+/+ 129/B6) were backcrossed similar to the C3-/- 129/B6 mice. The C3-/- mice on the C57BL/6 (B6) background were generated by backcrossing the C3-/- 129/B6 to the C57BL/6 (10 generations). The generation and characterization of CR1/CR2-/- mice has been described previously (20). Wild-type B6 mice were purchased from the National Cancer Institute (Bethesda, MD). All animal experiments were performed as per institutional animal care guidelines.
Virus
Mice were infected with 2 x 105 PFU of the Armstrong strain of LCMV (LCMV-Arm) by i.p. injection (21). Infectious LCMV in the tissues was quantitated by a plaque assay using Vero cell monolayers as described elsewhere (21).
Cytotoxicity assay
The MHC class I-restricted cytotoxic activity in the spleen was measured by a 51Cr-release assay using MC57G target cells as described previously (21, 22).
Intracellular cytokine staining
The number of LCMV-specific cytokine-producing CD8 T cells in
the spleen was quantitated by staining for intracellular IFN-
as
described previously (22). Briefly, splenocytes were
cultured for 5 h with or without the LCMV CTL epitope peptides in
the presence of brefeldin A. After culture, cells were stained for cell
surface CD8 and intracellular IFN- using the Cytofix/Cytoperm kit
(BD PharMingen, La Jolla, CA). The number of IFN--producing CD8 T
cells was determined by flow cytometry using a FACScan or FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA). The flow cytometry data
were analyzed using CellQuest software (BD Biosciences).
Quantitation of LCMV-specific CD8 T cells using MHC I tetramers
The production and use of MHC I tetramers (Db) specific to the two immunodominant epitopes present in the LCMV nucleoprotein (NP396-404) and glycoprotein (gp33–41) have been described elsewhere (22). Single cell suspensions of splenocytes were stained with allophycocyanin-labeled MHC I tetramers, PE-labeled anti-CD8 Abs, and FITC-labeled anti-CD44 Abs at 4°C for 1 h. After staining, cells were fixed in 2% paraformaldehyde and samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences). All Abs were purchased from BD PharMingen.
Flow cytometry
To examine the expression of complement receptors on LCMV-specific CD8 T cells, single cell suspensions of spleen were costained with MHC class I tetramers (specific to nucleoprotein (NP) 396–404) and FITC-labeled anti-CR1/2 (7G6, 7E9), anti-CR3 (Mac-1), or anti-C5aR Abs and analyzed by flow cytometry. To determine the expression of MHC I (Db) on macrophages and B lymphocytes, splenocytes were stained with anti-CD8 (BD PharMingen), anti-Mac-1 (BD PharMingen), anti-CD19 (Caltag Laboratories, Burlingame, CA), and anti-Db (BD PharMingen) Abs. Macrophages and B cells were identified based on being Mac-1-positive CD8-negative and CD19-positive, respectively.
Statistical analysis
Data were analyzed using the commercially available statistical
software (Systat version 8.0, Chicago, IL). Groups were compared by the
Student’s t test and significance was defined at
p 
0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
C3 levels and/or activity can vary between inbred strains of mice (23, 24, 25). Our studies have also shown that serum levels of C3 in 129/B6 mice are significantly lower than in B6 mice (data not shown). Because the regulatory role of C3 on T cell responses may depend upon the genetic background of the mice, we compared Ag-specific CD8 T cell responses to LCMV infection between wild-type (+/+) and C3-/- mice on both 129/B6 and B6 backgrounds. It is worth mentioning that the MHC haplotype of both 129/B6 and B6 mice is H-2b. Groups of +/+ 129/B6, C3-/- 129/B6, +/+ B6, and C3-/- B6 mice were infected with LCMV and on day 8 postinfection (PI), we measured MHC class I-restricted cytotoxicity in the spleens directly ex vivo. As shown in Fig. 1a, the spleens of LCMV-infected +/+ 129/B6 exhibited potent cytotoxic activity on virus-infected targets. The cytotoxic activity in the spleens of C3-/- 129/B6 mice was comparable to that of +/+ 129/B6 mice. Similarly, the LCMV-specific cytotoxic activities in the spleens of +/+ B6 and C3-/- B6 mice were alike (Fig. 1b). The CTL assays performed on LCMV-infected targets did not reveal any epitope-specific differences in the cytotoxic activity of CD8 T cells between +/+ and C3-/- mice. To address this issue, groups of +/+ B6 and C3-/- B6 mice were infected with LCMV-Arm, and MHC I-restricted cytotoxic activity against various LCMV CTL epitopes was quantitated using peptide-pulsed target cells (Fig. 1c). As shown in Fig. 1c, splenocytes from +/+ B6 mice exhibited specific cytotoxic activity against multiple epitopes, and the relative levels of cytotoxicity clearly demonstrate the immunodominance hierarchy of the anti-LCMV CTL response in C57BL/6 mice (22). Fig. 1c also shows that the splenocytes from LCMV-infected C3-/- B6 mice showed potent killing against all the LCMV CTL epitopes in a manner consistent with the epitope hierarchy of the LCMV-specific CTL response. However, splenocytes from LCMV-infected C3-/- B6 mice showed a clear tendency of lower cytotoxic activity (<2-fold) against most of the epitopes, as compared with +/+ B6 mice (Fig. 1c). Studies to compare CTL activity against several LCMV epitopes between +/+ 129/B6 and C3-/- B6 mice yielded similar results (data not shown). Taken together, these data show that C3 deficiency did not significantly (p < 0.05) affect the generation of MHC class I-restricted cell-mediated cytotoxic activity during an acute LCMV infection.
|
50%, as compared
with +/+ B6 mice. Comparison of the total number of LCMV-specific CD8 T
cells in the spleens between +/+ B6 and C3-/-
B6 mice revealed that C3 deficiency reduced the expansion of
NP396–404-specific CD8 T cells by 2-fold (Fig. 2d). C3
deficiency had a more pronounced effect on the expansion of
gp33–41-specific CD8 T cells in B6 mice; the spleens of
C3-/- B6 mice contained an 4-fold lower
number of gp33–41-specific CD8 T cells, as compared with those of +/+
B6 mice (Fig. 2d). This reflects a 75% reduction in the
expansion of gp33–41-specific CD8 T cells in
C3-/- B6 mice, as compared with +/+ B6 mice.
These data show that in C57BL/6 mice, the expansion of
gp33–41-specific CD8 T cells seem to be more C3-dependent, as compared
with NP396–404-specific CD8 T cells. This is in striking contrast to
129/B6 mice, where C3 deficiency resulted in selective diminution in
the expansion of NP396–404-specific CD8 T cells (Fig. 2, a
and b). In summary, these data suggest that C3
1) promotes expansion of CD8 T cells and 2)
may regulate epitope selection during T cell responses.
|
8-
to 10-fold higher, as compared with +/+ 129/B6 mice (Fig. 3). However,
in mice on the B6 background, LCMV clearance was minimally affected by
C3 deficiency; on day 8 PI, extremely low levels of LCMV were detected
in the spleens of both +/+ B6 and C3-/- B6
(data not shown).
|
and elicit contact sensitivity in mice
(29, 30). We next used intracellular cytokine staining to
determine whether C3 deficiency affected the: 1) CD8 T cell responses
to subdominant epitopes and 2) ability of CD8
T cells to produce IFN-. As shown in
Table I and Fig. 4, the anti-LCMV CD8
T cell response in the +/+ B6 mice exhibited a distinct epitope
hierarchy. This CD8 T cell epitope hierarchy was not affected by C3
deficiency. However, the frequencies of LCMV-specific CD8 T cells in
C3-/- B6 mice were substantially reduced, as
compared with +/+ B6 mice. The differences were more dramatic when
absolute numbers of LCMV-specific CD8 T cells were compared between
LCMV-infected +/+ B6 and C3-/- B6 mice (Fig. 4). The total number CD8 T cells specific to the epitopes in the viral
glycoprotein was significantly reduced in C3-/-
B6 mice, as compared with +/+ B6 mice; CD8 T cell responses to the
epitopes in the viral NP tended to be less affected by C3 deficiency
(Fig. 4). In comparison to +/+ B6 mice, the expansion of CD8 T cells
specific to the epitopes in the viral NP and glycoprotein was reduced
by 50% and 66%, respectively, in the
C3-/- B6 mice. It is worth pointing out that
the gp33–41 peptide is presented by both Db and
Kb MHC I molecules. Although both
Db- and Kb-restricted
gp33–41-specific CD8 T cells are detected by intracellular cytokine
staining, only Db-restricted gp33–41-specific
CD8 T cells bind MHC class I tetramers (31). This explains
why intracellular cytokine data for gp33–41-specific CD8 T cells did
not exactly mirror the numbers obtained by MHC I tetramer staining (as
compared with +/+ mice, C3-deficient mice had 4-fold and 3-fold fewer
gp33–41-specific CD8 T cells as measured by MHC I tetramers and
intracellular cytokine staining, respectively; Figs. 2d and
4). Intracellular cytokine staining was also used to compare
LCMV-specific CD8 T cell responses to multiple epitopes between +/+
129/B6 and C3-/- 129/B6 mice. These studies
showed that NP396–404-specific CD8 T cell responses were selectively
inhibited in C3-/- 129/B6 mice as compared with
+/+ 129/B6 mice (data not shown).
|
|
Active cleavage products of C3 modulate lymphocyte function via binding to CR1 and 2 (9). It has been shown previously that CR1 and CR2 are expressed on T cells and may be involved in the genesis of T cell-dependent autoimmune myocarditis in mice (16). Data presented in Figs. 2 and 4 showed that C3 activity might be important for optimal proliferation of LCMV-specific CD8 T cells. We determined whether C3 regulates LCMV-specific CD8 T cell responses via CR1 and CR2. To address this issue, we compared the generation of LCMV-specific CD8 T cell responses between +/+ B6 and CR1/CR2-/- mice. Eight days following LCMV infection, we assessed MHC class I-restricted cytotoxic activity in the spleens of +/+ B6 and CR1/CR2-/- mice. As shown in Fig. 5, the cytotoxic activity in the spleens of CR1/CR2-/- mice was similar to that of +/+ B6 mice. We also examined the activation and expansion of LCMV-specific CD8 T cells using MHC class I tetramers. As illustrated in Fig. 6a, the relative proportions of CD8 T cells specific to the immunodominant epitopes NP396–404 and gp33–41 were comparable between +/+ B6 and CR1/CR2-/- mice. Further, the absolute numbers of NP396–404- and gp33–41-specific CD8 T cells in the spleens of CR1/CR2-/- mice were similar to those of +/+ B6 mice (Fig. 6b). Intracellular cytokine staining was performed to assess the effect of CR1/CR2 deficiency on the expansion of CD8 T cells specific to multiple LCMV CTL epitopes. CR1/CR2 deficiency had minimal effects (statistically insignificant) on the activation and expansion of CD8 T cells specific to both dominant (NP396, gp33, and gp34) and subdominant (gp276, gp118, and NP205) epitopes (data not shown). Taken together, these data suggest that generation of LCMV-specific CD8 T cell responses is independent of CR1/CR2. Consistent with these findings, in +/+ mice, NP396–404-specific CD8 T cells did not express detectable levels of CR1/2 on their surface. However, a subpopulation of LCMV-specific CD8 T cells expressed cell surface CR3 (Mac-1) and CR5aR (data not shown).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
It is becoming increasingly evident that components of innate immunity
modulate the specific immune response. Although the importance of
complement proteins in regulating humoral immunity is well documented,
the role of C3 in orchestrating T cell responses has been unclear
(13, 20). However, recent studies have ascribed a role for
complement in the elicitation of T cell responses in mice. Depletion of
C3 protected mice against T cell-dependent autoimmune myocarditis
(16). In C3-/- mice, the
development of T cell-dependent autoimmune allergic encephalitis was
attenuated (32). Upon infection with influenza virus,
C3-deficient mice exhibited poor viral clearance on account of
suboptimal activation and trafficking of CD4 and CD8 T cells to the
lung (17). In kidney and skin transplant models, local
synthesis of C3 was shown to be essential for T cell priming and
rejection of allografts (18, 30). These studies showed
that C3 plays an important role in T cell activation, in organ-specific
autoimmunity, in transplant rejection, and in a localized infection.
Our studies confirm and extend these findings. In our studies, we
investigated the role of C3 in the generation of Ag-specific T cell
responses to multiple epitopes during a systemic viral infection of
mice with LCMV. We show that C3 activity affects priming and expansion
of LCMV-specific CD8 T cells in an epitope-dependent fashion. In 129/B6
mice, loss of C3 results in a selective decrease in the expansion of
CD8 T cells specific to the epitope, NP396–404 (Fig. 2, a
and b). In B6 mice, CD8 T cell responses to the gp-derived
epitopes were markedly reduced by C3 deficiency, as compared with NP
epitopes (Figs. 2, c and d). Discussion of the
mechanism(s) underlying the differential effect of C3 deficiency on the
epitope selection (NP396 vs gp33–41) in 129/B6 and B6 mice is purely
speculative. Differences in the genetic background of the mice may
influence the efficiency of processing and presentation of the
NP396–404 and gp33–41 peptides. As a result, the C3 dependency of
peptide processing and presentation may vary from one strain to the
other. Why are CD8 T cell responses to some epitopes more affected by
C3 deficiency within the 129/B6 or B6 mice? It is worth noting that the
same class I MHC molecule (Db) presents both
NP396–404 and gp33–41 epitopes in 129/B6 (H-2b)
and B6 (H-2b) mice. Further, our studies in
LCMV-infected +/+ B6 and C3-/- B6 mice showed
that C3 deficiency did not affect the cell surface expression of
Db molecules on macrophages and B cells (data not
shown). Therefore, at least in the B6 mice, the C3 deficiency-induced
epitope-specific inhibition of CD8 T cell responses cannot be
attributed to the differences in levels of Db
expression on APCs. Previous studies have shown that lack of
costimulatory interactions (CD28/B7 or CD40L/CD40) or CD4 deficiency
did not affect the epitope hierarchy of the LCMV-specific CD8 T cell
response (33, 34, 35). Therefore, it is less likely that
costimulation or CD4 T cell help are factors in C3-dependent epitope
selection in LCMV-infected mice. It was recently shown that epitope
selection can be influenced by IFN- during an infection of mice with
Listeria monocytogenes (36). However, the role
of IFN- in regulating epitope selection during an acute LCMV
infection is not known. The mechanism(s) regulating the epitope
hierarchy of the anti-LCMV CD8 T cell responses are not well
understood. The role of C3 in epitope selection during an acute LCMV
infection warrants further investigation. Nonetheless, our studies
suggest that the complement system, an important element of the innate
immune response can interfere with T cell epitope selection. The level
of C3, a changing parameter in the course of systemic inflammation,
might interfere with immunodominance.
Several phenomena have been described that could explain how C3 promotes expansion of LCMV-specific CD8 T cells. It has been previously shown that complement factors can directly interact with T cells and can modulate the function of Ag presenting T cells, which are crucial for T cell expansion (15, 16, 37, 38, 39, 40). CD46, a receptor that interacts with complement products C3b and C4b, is expressed on all nucleated cells, including T cells (41). Depending on the isoform of CD46, C3b and C4b can either augment or suppress CD8 T cell responses (42). When both isoforms of CD46 are coexpressed on a T cell, stimulatory effects seem to dominate over suppressive effects (42). Therefore, in the LCMV infection in C3-/- mice, abrogation of CD46/C3b interactions might have reduced expansion of virus-specific CD8 T cells.
It has been shown that Ag-bound C3b enhances the efficiency of Ag presentation to T cells (43, 44). Although the underlying mechanisms are still unclear, it has been reported that C3 deposition on APCs augments T cell proliferation (40, 45). Taken together, these reports suggest that lack of C3 activity can also affect the efficiency of Ag presentation, thereby limiting the expansion of LCMV-specific CD8 T cells in vivo. Moreover, complement activation products iC3b/C3dg bind to Ag/natural Ab complexes and promote Ag uptake and expression of costimulatory molecules by APCs (46). Although CD4-deficient and B cell-deficient mice develop normal CD8 T cell responses to an acute LCMV infection, the role of Abs needs further investigation (35, 47).
Products of complement activation can modulate cellular responses via complement receptors CR1 and CR2, which are predominantly expressed on APCs including B cells (9). CR1/CR2 signaling in B cells regulates activation threshold, Ag uptake, processing and presentation, isotype switching, and generation of memory B cells (9). Moreover, expression of CR1/CR2 on T cells has been reported, and may promote binding between the APC and T cells via C3 (16, 40, 45). Therefore, C3 can regulate T cell responses by interacting directly with T cells or indirectly via APCs. Our studies in CR1/CR2-/- mice clearly show that CR1/CR2 signaling is not obligatory for optimal activation and expansion of LCMV-specific CD8 T cells (Fig. 6). Similar to our findings, generation of CD8 T cell responses to influenza infection in mice is dependent upon C3, but independent of CR1/CR2 signaling (17).
C3 might regulate CD8 T cell responses by its influence on cell trafficking. The chemotactic and proinflammatory activities of C3a and C5a, which are the cleavage products of C3 and C5, respectively, are well documented. Activated T lymphocytes can express functional receptors for C3a (C3aR) and C5a (C5aR) (48, 49), that influence trafficking in inflammatory disorders (48, 49). Further, C5a may affect the trafficking of dendritic cells and initiation of immune responses (50). Hence, it is plausible that during LCMV infection, lack of C3 activity (and subsequent C5 activity) might hinder recruitment, trafficking, and optimal priming of CD8 T cells. It is worth emphasizing that all the mechanisms listed above by which C3 may regulate the generation of LCMV-specific CD8 T cell responses are not mutually exclusive. Further mechanistic studies are warranted to examine the above-listed hypotheses. Nevertheless, the data presented in this paper provide compelling evidence for an important role for C3 in epitope selection and expansion of virus-specific CD8 T cells during a systemic infection. These findings have implications in devising immunotherapeutic modalities in the treatment of autoimmune diseases and prevention of transplant rejection.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. M. Suresh, Department of Pathobiological Sciences, University of Wisconsin, 2015 Linden Drive, Madison, WI 53706. E-mail address: sureshm{at}svm.vetmed.wisc.edu
3 Abbreviations used in this paper: CR, complement receptor; LCMV, lymphocytic choriomeningitis virus; NP, nucleoprotein; PI, postinfection.
Received for publication August 13, 2002. Accepted for publication November 13, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
: a possible initiating role of B cells. J. Exp. Med. 186:1015.. Science 290:1354.-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J. Leukocyte Biol. 69:69.This article has been cited by other articles:
|
|
 |
|
  Q. Peng, K. Li, N. Wang, Q. Li, E. Asgari, B. Lu, T. M. Woodruff, S. H. Sacks, and W. Zhou Dendritic Cell Function in Allostimulation Is Modulated by C5aR Signaling J. Immunol., November 15, 2009; 183(10): 6058 - 6068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Jacobson, K. M. Roundy, J. J. Weis, and J. H. Weis Regulation of Murine Splenic B Cell CR3 Expression by Complement Component 3 J. Immunol., September 15, 2009; 183(6): 3963 - 3970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakayama, S.-I. Kim, E. H. Kim, J. D. Lambris, M. Sandor, and M. Suresh C3 Promotes Expansion of CD8+ and CD4+ T Cells in a Listeria monocytogenes Infection J. Immunol., September 1, 2009; 183(5): 2921 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pavlov, H. Raedler, S. Yuan, S. Leisman, W.-h. Kwan, P. N. Lalli, M. E. Medof, and P. S. Heeger Donor Deficiency of Decay-Accelerating Factor Accelerates Murine T Cell-Mediated Cardiac Allograft Rejection J. Immunol., October 1, 2008; 181(7): 4580 - 4589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ghannam, M. Pernollet, J.-L. Fauquert, N. Monnier, D. Ponard, M.-B. Villiers, J. Peguet-Navarro, A. Tridon, J. Lunardi, D. Gerlier, et al. Human C3 Deficiency Associated with Impairments in Dendritic Cell Differentiation, Memory B Cells, and Regulatory T Cells J. Immunol., October 1, 2008; 181(7): 5158 - 5166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Lalli, M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and P. S. Heeger Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis Blood, September 1, 2008; 112(5): 1759 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Girgis, B. C. DeHaven, X. Fan, K. M. Viner, M. Shamim, and S. N. Isaacs Cell Surface Expression of the Vaccinia Virus Complement Control Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected Cells from Complement Attack J. Virol., May 1, 2008; 82(9): 4205 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Lalli, M. G. Strainic, F. Lin, M. E. Medof, and P. S. Heeger Decay Accelerating Factor Can Control T Cell Differentiation into IFN-{gamma}-Producing Effector Cells via Regulating Local C5a-Induced IL-12 Production J. Immunol., November 1, 2007; 179(9): 5793 - 5802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fang, T. Miwa, H. Shen, and W.-C. Song Complement-Dependent Enhancement of CD8+ T Cell Immunity to Lymphocytic Choriomeningitis Virus Infection in Decay-Accelerating Factor-Deficient Mice J. Immunol., September 1, 2007; 179(5): 3178 - 3186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, Y. Kimura, C. Fang, L. Zhou, G. Sfyroera, J. D. Lambris, R. A. Wetsel, T. Miwa, and W.-C. Song Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo Blood, July 1, 2007; 110(1): 228 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Hogan, D. O. Co, J. Karman, E. Heninger, M. Suresh, and M. Sandor Virally Activated CD8 T Cells Home to Mycobacterium bovis BCG-Induced Granulomas but Enhance Antimycobacterial Protection Only in Immunodeficient Mice Infect. Immun., March 1, 2007; 75(3): 1154 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mehlhop and M. S. Diamond Protective immune responses against West Nile virus are primed by distinct complement activation pathways J. Exp. Med., May 15, 2006; 203(5): 1371 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Peng, K. Li, H. Patel, S. H. Sacks, and W. Zhou Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype J. Immunol., March 15, 2006; 176(6): 3330 - 3341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fairweather, S. Frisancho-Kiss, D. B. Njoku, J. F. Nyland, Z. Kaya, S. A. Yusung, S. E. Davis, J. A. Frisancho, M. A. Barrett, and N. R. Rose Complement Receptor 1 and 2 Deficiency Increases Coxsackievirus B3-Induced Myocarditis, Dilated Cardiomyopathy, and Heart Failure by Increasing Macrophages, IL-1beta, and Immune Complex Deposition in the Heart J. Immunol., March 15, 2006; 176(6): 3516 - 3524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhou, H. Patel, K. Li, Q. Peng, M.-B. Villiers, and S. H. Sacks Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells Blood, March 15, 2006; 107(6): 2461 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Heeger, P. N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, Y. Xu, and M. E. Medof Decay-accelerating factor modulates induction of T cell immunity J. Exp. Med., May 16, 2005; 201(10): 1523 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W.-C. Song The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo J. Exp. Med., February 22, 2005; 201(4): 567 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. J. Kim, I. D. Dimitriou, M. C. H. Holland, D. Mastellos, Y. M. Mueller, J. D. Altman, J. D. Lambris, and P. D. Katsikis Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses J. Immunol., August 15, 2004; 173(4): 2524 - 2529. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
